InSilicoTrials Joins Microsoft for Startups Pegasus Program to Enhance AI-Driven Drug Development and Clinical Trials
InSilicoTrials, a health tech company pioneering simulation-based solutions for drug development, has been accepted into the Microsoft for Startups Pegasus Program. This invitation-only initiative, aimed at accelerating the growth of high-potential startups, is a significant milestone for InSilicoTrials as it seeks to revolutionize healthcare R&D through AI and in silico simulation technologies. The Pegasus Program provides growth-stage startups with access to Microsoft’s extensive global sales channels and enterprise customer network. It targets sectors such as AI, healthcare, cybersecurity, and retail, focusing on companies with a proven product-market fit and the potential to scale. InSilicoTrials will leverage Microsoft Azure’s cloud infrastructure and AI capabilities to enhance its digital simulation platform. This platform supports pharmaceutical and biotech companies, as well as researchers, in speeding up R&D, refining clinical trial designs, and lowering reliance on conventional clinical studies. InSilicoTrials' technology encompasses digital twin and virtual patient models, AI-driven simulations, and privacy-protected synthetic patient populations, all of which are designed to improve the efficiency and effectiveness of drug development. Luca Emili, CEO of InSilicoTrials, stated, "We are dedicated to expanding access to simulation and AI tools that help life sciences organizations reduce risks and expedite the development of safer, more effective treatments. Joining the Microsoft for Startups Pegasus Program will enable us to scale our reach, integrate more deeply with Microsoft Azure, and extend the benefits of in silico trials to a broader global audience." Through this partnership, InSilicoTrials will offer its solutions on the Azure Marketplace, simplifying access for enterprise customers. Additionally, the company will collaborate with Microsoft’s technical and sales teams to participate in co-sell opportunities and joint go-to-market strategies. Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups, expressed her enthusiasm: "We are delighted to welcome InSilicoTrials into the Pegasus Program. Their advanced digital simulation and AI technologies have the potential to significantly transform healthcare by accelerating innovation and drug development. We are excited to support them in bringing these solutions to the life sciences industry." For more information about InSilicoTrials and its innovative healthcare solutions, visit their website at https://insilicotrials.com/. About InSilicoTrials InSilicoTrials is a cloud-based digital health startup founded by experts in life sciences, cybersecurity, and digital innovation. The company’s platform uses AI and simulation to predict drug safety and efficacy, streamline R&D, and optimize clinical trial processes. With a global network of over 70 scientific partners and hundreds of integrated models, InSilicoTrials is playing a crucial role in modernizing and enhancing drug development workflows for pharmaceutical, biotech, and research organizations.